Molecular Templates, Inc.
http://mtem.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Molecular Templates, Inc.
Finance Watch: Signs Of Life? A Small Offering, Three New Filings And Galderma Hints At An IPO
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Threshold Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice